Abstract: A method is claimed based on CEST procedure for the in vivo or in vitro determination of physical or chemical parameters which includes the use of a responsive paramagnetic CEST contrast agent.

Abstract: The present invention relates to a process for preparing olefin polymers by polymerization or copolymerization of at least one olefin of the formula Ra—CH?CH—Rb, where Ra and Rb are identical or different and are each a hydrogen atom or a hydrocarbon radical having from 1 to 20 carbon atoms, or Ra and Rb together with the atoms connecting them can form a ring, at a temperature of from ?60 to 200° C. and a pressure of from 0.

Abstract: A fluorescent image-printed article including a substrate, and an image formed on the substrate, wherein the image is formed from a fluorescent ink containing a binder, and a fluorescent substance which is dispersed in the binder, is capable of emitting fluorescence when irradiated with ultraviolet rays, and is substantially transparent to visible light, the fluorescent substance being formed of a rare earth complex containing, as a ligand, a compound represented by the following formula (1):

Abstract: The present invention provides metal-containing compounds that include at least one ?-diketiminate ligand, and methods of making and using the same. In some embodiments, the metal-containing compounds are homoleptic complexes that include unsymmetrical ?-diketiminate ligands. In other embodiments, the metal-containing compounds are heteroleptic complexes including at least one ?-diketiminate ligand. The compounds can be used to deposit metal-containing layers using vapor deposition methods. Vapor deposition systems including the compounds are also provided. Sources for ?-diketiminate ligands are also provided.

Abstract: Luminescent chemical reagents that include complexes of rare earth metals with ligands such as aromatic heterocyclic nitrogen-containing compounds and semi-aromatic oxygen-containing compounds are used to detect small quantities of complex substances such as pharmaceuticals, metabolites, and microorganisms in complex sample mixtures.

Abstract: An exemplary optical limiter device (100) has an optically transmissive substrate (102) and a layer (104) on a first surface (106) of the substrate, the layer having a trimetallic nitride endohedral metallofullerene. The layer can be a thin film of the trimetallic nitride endohedral metallofullerene, a layer material with a cavity containing a solution with the trimetallic nitride endohedral metallofullerene, a sol-gel with a trimetallic nitride endohedral metallofullerene, and a self assembled monolayer with a trimetallic nitride endohedral metallofullerene. The layers of trimetallic nitride endohedral metallofullerenes can be vapor deposited, solution deposited and/or self assembled onto optical components. The third-order nonlinear properties of these films provide desired transmission characteristics.

Abstract: Provided is a method for synthesizing a rare-earth oxo isopropoxide safely with a high yield, using a rare-earth metal, which is more inexpensive than anhydrous rare-earth chlorides, as a raw material. In a solvent containing 90% or more by weight of isopropyl alcohol, a rare-earth metal and isopropyl alcohol are caused to react with each other in the presence of a mercury compound catalyst, a solvent is added thereto or the solvent is partially replaced, and then in a solvent containing 25% or more by weight of an aromatic hydrocarbon solvent having 6 to 10 carbon atoms or a saturated hydrocarbon solvent having 5 to 12 carbon atoms, water is added to conduct partial hydrolysis reaction, thereby synthesizing a rare-earth oxoisopropoxide.

Abstract: The invention relates to a polymerizable composition which is characterized in that it contains at least one filler that is surface-functionalized with groups of formula (I), wherein groups of formula (I) (A)a-Z-Y—R2—SiR13?m—(O—)m ??(I), are bonded to the filler via at least one oxygen atom that is bound to the silicon atom of the group of formula (I). The invention also relates to a process for the preparation of the composition according to the invention and its use in particular as a dental material.

Abstract: Metal-containing complexes of a tridentate beta-ketoiminate, one embodiment of which is represented by the structure: wherein M is a metal such as calcium, strontium, barium, scandium, yttrium, lanthanum, titanium, zirconium, vanadium, tungsten, manganese, cobalt, iron, nickel, ruthenium, zinc, copper, palladium, platinum, iridium, rhenium, osmium; R1 is selected from the group consisting of alkyl, alkoxyalkyl, fluoroalkyl, cycloaliphatic, and aryl, having 1 to 10 carbon atoms; R2 is selected from the group consisting of hydrogen, alkyl, alkoxy, cycloaliphatic, and aryl; R3 is linear or branched selected from the group consisting of alkyl, alkoxyalkyl, fluoroalkyl, cycloaliphatic, and aryl; R4 is a branched alkylene bridge with at least one chiral center; R5-6 are individually linear or branched selected from the group consisting of alkyl, fluoroalkyl, cycloaliphatic, aryl, and can be connected to form a ring containing carbon, oxygen, or nitrogen atoms; n is an integer equal to the valence of the metal

Abstract: A rare-earth fluorescent complex which forms a fluorescent complex with two or more rare-earth metals such as europium and terbium and can effectively be excited at a wavelength of 340 nm or longer; a fluorescent labeling agent comprising the rare-earth fluorescent complex; a method of fluorescent labeling in which the rare-earth fluorescent complex is used as a labeling agent; and a method of fluorometric analysis in which the fluorescent labeling agent is used. The rare-earth fluorescent complex is characterized by having a cyclic ligand comprising a 4-biphenyl-2,2?:6?,2?-terpyridine skeleton and a 2,6-bis(3?-aminomethyl-1?-pyrazolyl)pyrazine skeleton bonded thereto.

Abstract: A compound and methods of making thereof having the structure shown below is disclosed. Each Ar is an aromatic group. Each M is palladium, platinum, or rhenium. At least one X in the compound has an aliphatic having at least 1 carbon atom. Each x, each y, and each z is an integer greater than or equal to zero. Each m is an integer greater than or equal to one. n is an integer greater than or equal to three.

Abstract: Alkyl cyclopentadienyl precursors for use in ALD processes are disclosed. The present invention particularly relates to La alkyl cyclopentadienyl precursors, such as tris(isopropyl-cyclopentadienyl) Lanthanum.

Abstract: A method is claimed based on CEST procedure for the in vivo or in vitro determination of physical or chemical parameters which includes the use of a responsive paramagnetic CEST contrast agent.

Abstract: The present invention provides a process of preparation of naphthochlorins and other chlorins with annelated ring systems useful for photodynamic therapy and the compounds themselves. The method for producing naphthochlorin compounds include contacting compounds such as meso-(2?-hydroxymethyl)phenyl porphyrin or meso-(2?-N,N,N-trialkylaminomethyl)phenyl porphyrin precursors with at least one acid catalyst at sufficient temperature for a sufficient time to yield the desired conversion. In a similar manner chlorins possessing annelated ring systems may be made from compounds such as meso-(2?-hydroxymethyl)aryl porphyrins or meso-(2?-N,N,N-trialkylaminomethyl)phenyl porphyrin. The procedures described herein provide new routes for synthesizing naphthochlorins and chlorins with annelated ring systems.

Abstract: Systems, including compositions, kits, and methods, particularly for photoluminescence applications. The systems may include, among others, (1) organic chelators, (2) complexes between the chelators and lanthanide ions, and (3) precursors, derivatives, and uses thereof. The chelators may include a 1,4,7,10-tetraazacyclododecane ring system, for example, having the formula: Here, R1, R2, and R3 are substituents of the tetraazacyclododecane ring system, that is further substituted at the 10-position by a sensitizer Z that is typically a polyheterocyclic ring system. The organic chelator may be capable of forming a luminescent complex with a lanthanide ion, and is optionally further substituted by a reactive functional group or a conjugated substance. The resulting lanthanide complex may be useful in luminescence-based assays, such as energy transfer assays, among others.

Abstract: The invention relates to polyoxometalates represented by the formula (An)m+ [My(H2O)(p.y)X2W22O74(OH)2]m? or solvates or mixtures thereof, wherein A represents a cation, n is the number of the cations, m is the charge of the polyoxoanion, M represents a transition metal selected from Pd, Pt and mixtures thereof, y is 1, 2, 3 or 4, p is the number of water molecules bound to one M and varies from 3 to 5, and X represents a heteroatom selected from SbIII, BiIII, AsIII, SeIV and TeIV, a process for their preparation and their use for the catalytic oxidation of organic molecules.

Abstract: The present invention provides metal-containing compounds that include at least one ?-diketiminate ligand, and methods of making and using the same. In certain embodiments, the metal-containing compounds include at least one ?-diketiminate ligand with at least one fluorine-containing organic group as substituent. In other certain embodiments, the metal-containing compounds include at least one ?-diketiminate ligand with at least one aliphatic group as a substituent selected to have greater degrees of freedom than the corresponding substituent in the ?-diketiminate ligands of certain metal-containing compounds known in the art. The compounds can be used to deposit metal-containing layers using vapor deposition methods. Vapor deposition systems including the compounds are also provided. Sources for ?-diketiminate ligands are also provided.

Abstract: This invention relates to novel nucleotide-based compounds, methods of making radiolabeled compounds and use of such compounds for diagnostic imaging. Provided are compounds according to Formula (I) A-B-L-C, wherein A stands for an aptamer, B is absent or stands for a bridging structure, L is a linker, and C is a metal ion chelator. All substituents are defined in detail in the description. Preferred embodiments of said compounds bind to Tenascin-C.

Abstract: This invention provides a cochleate and nano-cochleate systems wherein the agents bridging lipid bilayer are organic multi-valent cations. This invention also provides a method for preparing the cochleate system comprising direct cochleation and hydrogel-isolated procedure. The preparation method comprises using the charge ration between the bridging agents and lipids to control the particle sizes. This cochleate or nano-cochleate system may be used for microencapsulation and delivery of therapeutics wherein the therapeutic agents are loaded in the cochleate structure as the bridging agents between lipid bilayers. Finally, this invention provides other uses of these new cochleate and nano- cochleate systems.

Abstract: The invention relates to a luminescent material for an light emitting device comprising an (YGd)-containing nanoparticle material linked to at least one organic ligand molecule

Abstract: The present invention has been developed for providing a method to easily manufacture a nanosized EuSe crystal which has been conventionally difficult to be manufactured. Heating the Eu(III) complex whose general formula is represented by the following formula generates an EuSe crystal having a particle size corresponding to the heating condition. Alternatively, the mixture composed of Eu(III) complex, a counter cation, and a solvent may be heated. Since the particle size of the nanosized EuSe crystals can be manipulated by the heating condition, the absorption wavelength of the EuSe crystals can be easily controlled. In addition, since it is easy to create a magnetooptic-responsive plastic using the high dispersibility of the EuSe crystals, it can be immediately applied to an optical isolator or other devices.

Abstract: Polyhydroxy hydrogensulfated trimetallic nitride endohedral metallofullerenes, can be utilized in a number of applications, for example, as proton conductors in electrochemical devices. The presence of encapsulated metal atoms, preferably trivalent metals including lanthanides, rare earths or HIB group metals, polyhydroxy hydrogensulfated trimetallic nitride endohedral metallofullerenes with properties not found in empty-cage polyhydroxy hydrogensulated fullerenes.

Abstract: There is provided rare earth metal complexes of formula (I): wherein M is a cation, RE is a rare earth metal; X is a counter anion; and R1, R2, R3, and R4 are each independently selected from hydrogen, alkyl of 1-8 carbon atoms, aryl, halo, and alkoxy. Also provided is a composition of europium bis(2,2?-bipyridine-N,N?)-trinitrate with a diketonate dopant. The disclosure also provides processes for preparing the rare earth metal complexes. A mark comprising the rare earth metal complexes, and a method of applying the mark, are disclosed. The rare earth metal complexes may be used in printing systems, and for security applications.

Abstract: A compound is represented by Structural Formula A1: C—B-L-A??A1 or a pharmaceutically acceptable salt or solvate thereof. A is a prostate specific membrane antigen (PSMA) ligand; L is an optionally substituted aliphatic or heteroaliphatic linking group; B includes at least one optionally substituted moiety selected from the group consisting of a sugar, a charged group, an aryl ring, and a heteroaryl ring, wherein B optionally includes a drug or a labeling agent; and C is H, a drug, or a labeling agent, wherein CB together comprises the drug or the labeling agent. The compounds are useful as PSMA agents and in pharmaceutical compositions, methods for treating and detecting diseases such as cancer in a subject, methods for identifying cancer cells in a sample, methods for inhibiting tumor neovascularization, methods for identifying drugs that can treat cancer, and the like.

Abstract: A process' for the modification of a particulate reactive filler for a dental ionomer cement, comprising (a) providing a particulate reactive filler; and (b1) treating the surface of the particulate reactive filler with a surface modifying agent for obtaining a surface modified particulate reactive filler displaying ligand groups for a transition metal; and (b2) treating the surface modified particulate reactive filler with an agent containing the transition metal for complexing the transition metal with the ligand groups displayed on the surface of the surface modified particulate reactive filler; and/or (c) treating the surface of the particulate reactive filler with a surface modifying transition metal complex which is a reaction product of a surface modifying agent and a transition metal precursor compound, for obtaining a transition metal complex surface modified particulate reactive filler for a dental ionomer cement.

Abstract: An oxygen-bridged bimetallic complex of the general formula (I) Cp2R1M1-O-M2R22Cp, ??(I) wherein Cp is independently a cyclopentadienyl, indenyl or fluorenyl ligand which can be substituted, or a ligand isolobal to cyclopentadienyl, R1, R2 independently are halide, linear or branched or cyclic alkyl, aryl, amido, phosphido, alkoxy or aryloxy groups, which can be substituted, M1 is Zr, Ti or Hf, and M2 is Ti, Zn, Zr or a rare earth metal. The complex can be useful as a polymerization catalyst.

Abstract: The invention is directed to a lanthamide chelate composition having a lanthamide, a charged amidate ligand, and a mono- or bidentate neutrally charged coordination compound, the composition being represented by structure I or structure II wherein Ln3+ designates lanthamide, R1 is alkyl, aryl, or heteroaryl; R2 is alkyl, aminoalkyl, aryl or heteroaryl; M is a neutrally charged monodentate coordination compound, M? is a neutrally charged bidentate coordination compound, a=1 or 2; and wherein M and M? comprise N, S, or O. It extends to the process of making the composition.

Abstract: The invention is directed to a composition having a lanthanide chelate being a lanthanide and a ligand wherein the ligand is represented by the formula wherein R1 is alkyl, aryl, or heteroaryl; R2 is alkyl, aminoalkyl, aryl or heteroaryl; with the proviso that R1 and R2 cannot both be phenyl, and with the proviso that R2 cannot be phenyl when R1 is alkyl.

Abstract: The present invention relates to a process for preparing a porous metal organic framework, which comprises the step: Reaction of at least one metal compound with at least one at least bidentate organic compound which can coordinate to the metal, where the metal is ScIII, YIII or a trivalent lanthanide and the organic compound has at least two atoms which are selected independently from the group consisting of oxygen, sulfur and nitrogen and via which the organic compound can coordinate to the metal, in the presence of a nonaqueous organic solvent, with the reaction being carried out with stirring and at a pressure of not more than 2 bar (absolute). The invention further relates to porous metal organic frameworks which have been prepared by this process and their use.

Abstract: A metal sulfide nanocrystal manufactured by a method of reacting a metal precursor and an alkyl thiol in a solvent, wherein the alkyl thiol reacts with the metal precursor to form the metal sulfide nanocrystals, wherein the alkyl thiol is present on the surface of the metal sulfide nanocrystal, wherein the alkyl thiol is bonded to the sulfur crystal lattice. A metal sulfide nanocrystal manufactured with a core-shell structure by a method of reacting a metal precursor and an alkyl thiol in a solvent to form a metal sulfide layer on the surface of a core, wherein the alkyl thiol is present on the surface of the metal sulfide nanocrystal, wherein the alkyl thiol is bonded to the sulfur crystal lattice. These metal sulfide nanocrystals can have a uniform particle size at the nanometer-scale level, selective and desired crystal structures, and various shapes.

Abstract: Novel pharmaceutical gallium compositions, including gallium complexes having increased oral bioavailablity relative to uncomplexed gallium salts are disclosed. Such compositions are useful in the treatment of conditions and diseases in which inhibition of abnormally increased calcium resorption is desired, including cancer, hypercalcemia, osteoporosis, osteopenia and Paget's disease. Methods for preparation and treatment are also provided.

Abstract: A fluorous delivery or recovery material comprising a fluorous support material having a coating thereon, the coating comprising an amount of a fluorous reaction component that may be dispensed using non-gravimetric methods is disclosed. Also disclosed are methods for dispensing a fluorous reaction component comprising dispensing by non-gravimetric methods a predetermined amount of the fluorous reaction component as a coating on a fluorous support material.

Abstract: The present invention is directed to low toxicity boronated compounds and methods for their use in the treatment, visualization, and diagnosis of tumors. More specifically, the present invention is directed to low toxicity glycosylated carborane-containing 5,10,15,20-tetraphenylporphyrin compounds and methods for their use particularly in boron neutron capture therapy (BNCT) and photodynamic therapy (PDT) for the treatment of tumors of the brain, and head and neck. The invention is also directed to using these glycosylated carborane-containing tetraphenylporphyrin compounds in methods of tumor imaging and/or diagnosis such as MRI, SPECT, or PET.

Abstract: New ligands and compositions with bridged bis-aromatic ligands are disclosed that catalyze the polymerization of monomers into polymers. These catalysts with metal centers have high performance characteristics, including higher comonomer incorporation into ethylene/olefin copolymers, where such olefins are for example, 1-octene, propylene or styrene. The catalysts also polymerize propylene into isotactic polypropylene.

Abstract: The invention relates generally to biotin-containing compounds that are useful as imaging agents and drug-delivery agents. Another aspect of the invention relates to the aforementioned compounds chelated to a metal atom. In a preferred embodiment, the metal atom is a gadolinium. Another aspect of the invention relates to a compound comprising three biotin moieties and a pharmaceutical agent covalently bound to a heterocyclic core. In certain embodiments, the pharmaceutical agent is an antibiotic, antiviral, or radionuclide. Another aspect of the present invention relates to a method of treating disease involving administering the compounds of the invention to a mammal. Another aspect of the present invention relates to a method of acquiring a magnetic resonance image using the compounds of the invention.

Abstract: The present invention provides metal-containing compounds that include at least one ?-diketiminate ligand, and methods of making and using the same. In certain embodiments, the metal-containing compounds include at least one ?-diketiminate ligand with at least one fluorine-containing organic group as a substituent. In other certain embodiments, the metal-containing compounds include at least one ?-diketiminate ligand with at least one aliphatic group as a substituent selected to have greater degrees of freedom than the corresponding substituent in the ?-diketiminate ligands of certain metal-containing compounds known in the art. The compounds can be used to deposit metal-containing layers using vapor deposition methods. Vapor deposition systems including the compounds are also provided. Sources for ?-diketiminate ligands are also provided.

Abstract: [PROBLEMS] To provide a metal complex compound capable of being suitably used for manufacturing a metal-containing thin film by the CVD method and a method for preparing a metal-containing thin film. [MEANS FOR SOLVING PROBLEMS] A metal complex compound comprising a ?-diketonato ligand having an alkoxyalkyl-methyl group, and a method for preparing a metal-containing thin film using the metal complex compound by the CVD method.

Abstract: Formula (I) compounds are described: Formula (I) where the radicals are as defined in the description, processes for their preparation, and their uses for the preparation of conjugates with radionuclides for use in human and animal therapy and diagnostics, particularly for the diagnosis and therapy of pathological conditions such as tumours.

Abstract: The present invention includes a paint or coating composition comprising an organic pigment or dye complexed to the surface of a layered or fibrous inorganic clay. A wide variety of paint colors can be obtained by varying the pH during the preparation as well as by varying the synthesis conditions and changing particle size of the clay. The paint has unprecedented stability.

Abstract: An electric device comprises a gelled acid electrolyte in complex with a lanthanide that forms a redox pair with a second element. Preferred electric devices include batteries, and especially primary batteries, while preferred acid electrolytes have a sulfonic acid group. Contemplated lanthanides especially include cerium, and preferred second elements particularly include zinc. Alternatively, contemplated electric devices may comprise a gelled electrolyte in which with a lanthanide forms a redox pair with zinc.

Abstract: The present invention includes a paint or coating composition comprising an organic pigment or dye complexed to the surface of a layered or fibrous inorganic clay. A wide variety of paint colors can be obtained by varying the pH during the preparation as well as by varying the synthesis conditions and changing particle size of the clay.

Abstract: Coordination complexes having at least two structural conformations are disclosed. The coordination complexes contain at least one metal center and at least one hemi-labile ligand, and change structural conformations due to the presence or absence of allosteric effectors. Methods of detecting an analyte using the coordination complexes are also disclosed.

Abstract: Materials and methods are provided for making nanoparticles having a core including metal and/or semiconductor atoms, which core is covalently linked to a plurality of ligands comprising a RNA ligand. The RNA ligands may include siRNA or miRNA. Also provided are uses of these nanoparticles in therapy and diagnosis.

Abstract: A process for producing a trivalent metal ion compound is provided. The process combines a trivalent metal organo-oxide M?OR1)3 with a dione under reaction conditions to yield a reaction product where R1 in each occurrence independently is a C1-C8 alkyl, C6-C12 cycloalkyl, or C6-C14 aryl; R2 in each occurrence independently is H, C1-C8 alkyl, C6-C12 cycloalkyl, or C6-C14 aryl; M is a trivalent main group or lanthanide metal ion of Al, Ga, In, Ti, Ce, Pr, Nd, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, Zr, or Lu, and n is 3 with the proviso that when M is Zr n is 4. The reaction product has impurity levels of the order of tens of parts per million by weight when formed from reagent grade M?OR1)3. The reaction product is isolated and freeze-dried without need for washing to preclude wash solution contamination.

Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.

Abstract: The present invention relates to a new optically active rare earth complex (1) represented by a general formula (1); (in the formula, X1 and X2 each independently represents a hydrogen atom, a halogen atom, an alkyl group having 1 to 4 carbon atoms or an alkoxyl group having 1 to 4 carbon atoms; Y1, Y2, Y3, and Y4, each independently represents a hydrogen atom, a halogen atom, or an alkyl group having 1 to 4 carbon atoms; R1 represents an alkyl group having 1 to 8 carbon atoms, a fluorine-substituted alkyl group having 1 to 8 carbon atoms, or a phenyl group: R2 is a group selected from the group consisting of (a) cyclopentadienyl groups, (b) phenyl groups, and (c) naphthyl groups).

Abstract: Diagnostic and therapeutic compositions in the form of complexes for enhancing transmembrane transport of a diagnostic or therapeutic agent and methods for their use. The complexes contain the ?, ?, or bis isomers of folate receptor-binding analogs of folate, a metal chelated by a ligand, and in one embodiment, a chemotherapeutic agent.

Abstract: A cationic Group 3 or Lanthanide metal complex for coordination polymerization of olefins is disclosed. The precursor metal complex is stabilized by an anionic multidentate ancillary ligand and two monoanionic ligands. The ancillary ligand and the transition metal form a metallocycle having at least five primary atoms, counting any ?-bound cyclopentadienyl group in the metallocycle as two primary atoms. Olefin polymerization is exemplified.

Abstract: An alkoxyalcohol adduct of rare earth monocarboxylate has the formula (I): M(R2—COO)3.(R1O(CH2)nOH)p ??(I) in which M is a rare earth element such as Pr, Nd, Pm, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb and Lu; R1 is an aliphatic hydrocarbon group having 1 to 4 carbon atoms or a substituted aliphatic hydrocarbon group having 3 to 6 carbon atoms; R2 is a hydrogen atom or an aliphatic hydrocarbon group having 1 to 4 carbon atoms which has or does not have a substituent; n is 2 or 3; and p is a number in the range of 0.5 to 3.

Abstract: A process for polymerizing 1-butene, optionally with up to 30% by mol of ethylene, propylene or an alpha olefin of formula CH2?CHT wherein T is a C3-C10 alkyl group, in the presence of a catalyst system obtainable by contacting a metallocene compound of formula (I) Wherein M is an atom of a transition metal; X, is a hydrogen atom, a halogen atoms or a hydrocarbon group; R1, R2, R5, R6, R7, R8 and R9 are hydrogen atoms or hydrocarbon groups; with the proviso that at least one of R6 or R7 is a C1-C20 alkyl group; R3 and R4 are C1-C20 alkyl groups; and an alumoxane and/or a compound capable of forming an alkyl metallocene cation.